2026-10-27 18:20:59 UTC#523373newconfirmednews
LBRX stock news
LBRX stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-10 12:00:00 UTC#441734newconfirmedpress release
LB Pharmaceuticals presents new LB-102 preclinical data and clinical program updates at ECNP Congress
globenewswireimportance 0.40trust 0.90LB Pharmaceuticals Inc. +0.30LB-102 +0.30European College of Neuropsychopharmacology 0+2 entities
2026-10-09 18:21:00 UTC#440048newconfirmednews
Canaccord Genuity initiates LB Pharmaceuticals (LBRX) at Buy with $65 price target
2026-10-05 17:19:00 UTC#415029newconfirmednews
Roth Capital cuts LB Pharmaceuticals (LBRX) price target to $35.00 from $37.00
2026-10-02 09:18:31 UTC#404140newconfirmednews
Needham initiates LB Pharmaceuticals at Buy with $68 price target, citing LB-102 clinical data
tradingviewimportance 0.40trust 0.70Needham & Company, LLC +0.30LB Pharmaceuticals, Inc. +0.50LB-102 +0.50+1 entities
2026-09-23 19:52:27 UTC#358114duplicateconfirmednews
LBRX's LB-102 shows efficacy in schizophrenia and mood disorders in ongoing clinical trials
2026-09-23 19:21:26 UTC#357969newconfirmednews
LBRX reports positive LB-102 efficacy in schizophrenia and mood disorders, Phase III data expected in 2027
2026-09-23 12:51:13 UTC#355481newconfirmednews
RBC Capital upgrades Lakefront Biotherapeutics to Outperform with $45 price target
tradingviewimportance 0.40trust 0.70RBC Capital Markets +0.30Lakefront Biotherapeutics +0.50gamgertamig +0.40
2026-09-15 12:13:02 UTC#313540newconfirmednews
LB Pharmaceuticals appoints former Centessa Pharmaceuticals executive Susan G. Kozauer as Chief Medical Officer
tradingviewimportance 0.30trust 0.90LB Pharmaceuticals +0.10Susan G. Kozauer +0.10Centessa Pharmaceuticals 0+1 entities
2026-08-24 20:43:00 UTC#214302duplicateconfirmednews
Lakefront Biotherapeutics Receives FDA Orphan Drug Designation for Gamgertamig to Treat Pemphigus
dow_jonesimportance 0.30trust 0.90Lakefront Biotherapeutics +0.50Food and Drug Administration +0.40Gilead Sciences +0.30+2 entities
2026-08-24 10:16:00 UTC#211385newconfirmednews
H.C. Wainwright & Co. raises LB Pharmaceuticals (LBRX) price target to $60.00 from $45.00
2026-08-11 21:20:08 UTC#161425newconfirmednews
LB Pharmaceuticals Inc. average analyst price target raised to $47.62, implying 4% upside
2026-08-11 15:30:00 UTC#159752newconfirmednews
RBC Capital maintains Sector Perform rating on Lakefront Biotherapeutics (LKFT)
2026-08-11 12:13:01 UTC#158552updateconfirmednews
LB Pharmaceuticals Q2 net loss $51.6M, cash $327.8M; pivots LB-102 to new indications
2026-08-11 12:12:19 UTC#158569updateconfirmednews
Lakefront Biotherapeutics reports positive late-stage trial results for LB-102 in neuropsychiatric indications
2026-08-11 05:21:10 UTC#156602duplicateconfirmednews
Lakefront Biotherapeutics H1 2026 net profit hits €16.6M following Ouro Medicines acquisition
2026-08-11 05:16:40 UTC#156585duplicateconfirmednews
Lakefront Biotherapeutics reports H1 2026 net profit of €16.6M and €2.24B cash position
2026-07-29 12:07:04 UTC#93887newconfirmedpress release
LB Pharmaceuticals (LBRX) Announces $150 Million Private Placement to Fund LB-102 Pipeline
2026-07-22 12:23:02 UTC#62834newconfirmednews
LB Pharmaceuticals accelerates Phase 3 NOVA-2 trial results for LB-102 to H1 2027
2026-07-21 09:43:00 UTC#56484newconfirmednews